Publications by authors named "E Hertervig"
Article Synopsis
- The study assessed long-term outcomes of vedolizumab (VDZ) over three years for patients with inflammatory bowel disease (IBD), specifically Crohn's disease (CD) and ulcerative colitis (UC).
- High continuation rates of VDZ treatment were observed, with 88% of CD patients and 87% of UC patients still on the medication after 104 weeks.
- Significant improvements were reported in clinical remission rates and health-related quality of life, with decreases in inflammatory markers, indicating VDZ is an effective long-term treatment for IBD.
Background: The combination of infliximab and immunosuppressant therapy is a standard management strategy for patients with Crohn's disease. Concerns regarding the implications of long-term combination therapy provided the rationale for a formal clinical trial of treatment de-escalation. Our aim was to compare the relapse rate and the time spent in remission over 2 years between patients continuing combination therapy and those stopping infliximab or immunosuppressant therapy.
View Article and Find Full Text PDFObjectives: Clinical trials demonstrated that golimumab is effective in anti-TNF naïve patients with ulcerative colitis. We aimed to assess the clinical effectiveness of golimumab in a real-world setting.
Materials And Methods: This was a prospective cohort study, conducted at 16 Swedish hospitals.
Background: Prospectively and systematically collected real-world data on vedolizumab are scarce. We aimed to assess the long-term clinical effectiveness of vedolizumab in inflammatory bowel disease (IBD).
Methods: This study was a prospective, observational, multicentre study.
Background & Aims: We investigated the effects of inducing deep remission in patients with early Crohn's disease (CD).
Methods: We collected follow-up data from 122 patients (mean age, 31.2 ± 11.